Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

NVO 56.65 +0.44 (0.78%)
price chart
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Trying to Increase Market Share
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Resubmits Application for Approval of Its ...
Hot Stocks on the Run: Alibaba Group Holding Ltd (NYSE:BABA), Novo Nordisk ...  wsnewspublishers
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Form 6-K NOVO NORDISK AS For: Mar 23
Closing Bell Reports: Textron Inc. (TXT), Novo Nordisk A/S (NVO), Isis ...  WallStreet Scope
Companies That Offer High Returns: Novo Nordisk A/S (ADR) (NYSE:NVO ...
Novo Nordisk A/S (ADR) (NYSE:NVO) was able to keep return on investment at 59.19% in the trailing twelve month while Reuters data showed that industry's average stands at 16.84% and sector's optimum level is 16.19%.
Healthcare Stocks Watch List - Novo (NVO), CVS (CVS), Glaxo (GSK ...  Techsonian (press release)
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Stocks with Downward Movements: Lam Research (LRCX), Novo Nordisk A/S ...
Novo Nordisk A/S (ADR) (NYSE:NVO) moved down -0.28% with the closing price of $56.21. The overall volume in the last trading session was 1.39 million shares.
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Latest Updates on Novo Nordisk A/S (ADR) (NYSE:NVO)
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).
Novo Nordisk (NVO) Searching For A New CEO  Bidness ETC
Related articles »